Trial Profile
Pivotal trial of naptumomab estafenatox as second-line therapy in patients with renal cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 Feb 2014
Price :
$35
*
At a glance
- Drugs Naptumomab estafenatox (Primary)
- Indications Renal cancer
- Focus Biomarker; Registrational; Therapeutic Use
- 18 Feb 2014 New trial record